( (vi) Description of Proposed Modifications to the Routine Cataract Removal With Intraocular Lens (IOL) Implantation Measure With the Newly Titled Cataract Removal With IOL Implantation Measure We finalized the Routine Cataract Removal with Intraocular Lens (IOL) Implantation cost measure in the CY 2019 PFS final rule (83 FR 59767 through 59773) for use in MIPS as an important measure of clinician cost performance, as cataract surgery is the most common surgical procedure in the United States
For drugs administered intravenously and supplied in containers containing 2 mL or less, like digoxin and phenobarbital, dosages are calculated based on body weight, potentially leading to discarded amounts
Congress has eliminated Part B coinsurance (section 1833(a)(1)(Y) of the Act, 410.152(l)(5)) and deductibles (section 1833(b)(1) of the Act) for covered prevention services recommended with a grade of A or B by the USPSTF
(2) The first applicable period for a Part D rebatable drug will be the earliest applicable period that follows the payment amount benchmark period identified in paragraphs (c)(1) through (4) of this section
We verwijzen zelf door en er wordt ook naar ons door verwezen
(3) Proposed Changes to Regulation Text As discussed in sections III.G.4.c.(2)(a), III.G.4.c.(2)(b), and III.G.4.c.(2)(c) of this proposed rule, we are proposing to establish scoring rules to calculate the MIPS Quality performance category score for ACOs reporting the APP Plus quality measure set for performance year 2025 and subsequent performance years
